Skip to content

Effect of Daily Nicotine Patch Application on Mechanical Ventilation Weaning in Smoking Patients

Multicentric Evaluation of a Daily Nicotine Patch Administration on Mechanical Ventilation Weaning in Smoking Patients Hospitalized in Intensive Care Unit

Status
UNKNOWN
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01104896
Acronym
NICOREA
Enrollment
600
Registered
2010-04-16
Start date
2010-01-31
Completion date
2012-02-29
Last updated
2010-04-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intensive Care, Mechanical Ventilation, Smoking

Keywords

Cigarette, tobacco, mechanical ventilation, nicotine

Brief summary

Nicotine patches are frequently used in smoking patients during their stay in the ICU in order to avoid tobacco's weaning symptoms which are likely to interfere with mechanical ventilation weaning. Until now the effectiveness of this treatment has not been proven. The aim of this study (NICOREA study) is to determine if a difference exists on the duration of mechanical ventilation once patients receive or not a nicotine substitute.

Detailed description

Six hundred mechanically ventilated patients are going to be enrolled to receive nicotine or placebo during a 24 month period in 14 centers in France.

Interventions

DRUGNicotine patch

One or two 15 mg nicotine patch(es) applied from 6am to 10 pm during 21 days

DRUGPlacebo

One or two placebo patch(es) applied from 6am to 10 pm each day for 21 days

Sponsors

Assistance Publique - Hôpitaux de Paris
CollaboratorOTHER
University of Paris 5 - Rene Descartes
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Age between 18 et 80 yrs * SOFA score below or equal to 16 at randomization time * Patient expected to be mechanically ventilated for at least 24hrs * Patient known to be usually smoking more than 10 cigarettes per day according to her/him or to a next of kin * Consent obtained from the patient or a next of kin.

Exclusion criteria

* Patients having been in the ICU for more than 72 hours or mechanically ventilated since more than 48 hours * Isolated brain trauma * Patients weaned from tobacco since more than 21 days * Patients smoking only pipe, cigars or cannabis * Chronic skin diseases (psoriasis, dermatitis, etc) * Patients receiving other products containing nicotine * Patients not understanding French * Patients with severe hearing deficiency * Mechanical ventilation weaning using an expert system * Disease with short term fatal issue * Pregnancy * Patient depending on other persons for most every day actions * Myocardial infarction within 3 months, ventricular arrhythmia's * Stroke during the 3 last months * Known hypersensibility to nicotine or patches

Design outcomes

Primary

MeasureTime frameDescription
Length of mechanical ventilation expressed in hours48 hours after extubationMeasured between the time of tracheal intubation to tracheal extubation without reintubation for at least 48 hours

Secondary

MeasureTime frame
Number of failure of mechanical ventilation weaningWithin the first 30 days
Incidence of score above +1 of the RASS scale measured every 4 hoursWithin the first 30 days
Number of days with delirium assessed by the CAM-ICU scoreWithin the first 30 days
Number of hours under sedation below RASS -4, between -3,-2, -2,+1 indexed by the overall duration of sedationWithin the first 30 days
Length of stay in the ICU expressed in day(s)Within the first 30 days
Number of pneumonia acquired during mechanical ventilationWithin the first 30 days
SOFA scorebetween 48 and 72 hrs
Tobacco weaning rate at hospital dischargeWithin the first 120 days
28th day mortality ratebetwwen 28th and 48th days
Number of self-extubation(s)Within the first 30 days

Countries

France

Contacts

Primary ContactShohreh Azimi
shohreh.azimi@sls.aphp.fr+33 1 44 84 17 79

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026